The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients
Richard P. Tobin(Society of Surgical Oncology), Martin D. McCarter(University of Colorado Cancer Center), Kimberly R. Jordan(University of Colorado Anschutz Medical Campus), Dana M. Davis(Dalhousie University)
Cited by 55
Related Papers
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial
|Journal of Clinical Oncology|2014|315
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
|JNCI Journal of the National Cancer Institute|2019|299
Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab
|International Immunopharmacology|2018|198